Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat + mFOLFIRINOX vs FOLFIRINOX in Metastatic Pancreatic Cancer
NCT03504423Phase 3Completed
- Sponsor
- Cornerstone Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of devimistat in pancreatic adenocarcinoma (PDAC), sponsored by Cornerstone Pharmaceuticals. Started Nov 2018; status: completed.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03504423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504423.